Reply to M. Voskoboynik et al

Affiliations

¹ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY hymand@mskcc.org.
² Memorial Sloan Kettering Cancer Center, New York, NY.
³ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.
⁴ The National Cancer Institute, Bethesda, MD.

Comment

David M Hyman et al. J Clin Oncol. 2014.

. 2014 Oct 1;32(28):3199-200.

doi: 10.1200/JCO.2014.56.5762. Epub 2014 Jul 28.

¹ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY hymand@mskcc.org.
² Memorial Sloan Kettering Cancer Center, New York, NY.
³ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.
⁴ The National Cancer Institute, Bethesda, MD.

No abstract available

Comment on

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.
Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, Iasonos A. Hyman DM, et al. J Clin Oncol. 2014 Feb 20;32(6):519-26. doi: 10.1200/JCO.2013.49.8808. Epub 2014 Jan 13. J Clin Oncol. 2014. PMID: 24419130 Free PMC article.
Improving patient selection for phase I oncology trials.
Voskoboynik M, Arkenau HT. Voskoboynik M, et al. J Clin Oncol. 2014 Oct 1;32(28):3198-9. doi: 10.1200/JCO.2014.55.8031. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071142 No abstract available.